Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database.

Literature DB >> 35513605

[¹⁷⁷Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database.

Jonathan Vigne^1,2,3, Basile Chrétien⁴, Anne-Laure Bignon⁵, Karine Bouhier-Leporrier⁵, Charles Dolladille⁶.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2022 PMID： 35513605 DOI： 10.1007/s00259-022-05833-6

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 10.057

Keyword Cloud
References

× No keyword cloud information.

4 in total

1. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors: Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal: N Engl J Med Date: 2017-01-12 Impact factor: 91.245

2. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.

Authors: Isaac Goncalves; Kate Burbury; Michael Michael; Amir Iravani; Aravind S Ravi Kumar; Tim Akhurst; Ing S Tiong; Piers Blombery; Michael S Hofman; David Westerman; Rodney J Hicks; Grace Kong
Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-11 Impact factor: 9.236

3. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

Authors: Jonathan R Strosberg; Martyn E Caplin; Pamela L Kunz; Philippe B Ruszniewski; Lisa Bodei; Andrew Hendifar; Erik Mittra; Edward M Wolin; James C Yao; Marianne E Pavel; Enrique Grande; Eric Van Cutsem; Ettore Seregni; Hugo Duarte; Germo Gericke; Amy Bartalotta; Maurizio F Mariani; Arnaud Demange; Sakir Mutevelic; Eric P Krenning
Journal: Lancet Oncol Date: 2021-11-15 Impact factor: 41.316

4. Salvage peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA,Tyr³]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

Authors: W A van der Zwan; T Brabander; B L R Kam; J J M Teunissen; R A Feelders; J Hofland; E P Krenning; W W de Herder
Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-28 Impact factor: 9.236

4 in total

[177Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database.

1. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

2. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.

3. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

4. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

[¹⁷⁷Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database.

1. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors.

3. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

4. Salvage peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA,Tyr³]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.